Cohort-level safety and efficacy results for [ 212 Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)–expressing neuroendocrine tumors (NETs): Cohorts 1–3.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Thorvardur Ragnar Halfdanarson, Richard L. Wahl, Vineeth Sukrithan, Brandon Robert Mancini, Seyed Ali Mosallaie, Savitha Balaraman, Gregory Sibley, Jason S. Starr, Lowell Brian Anthony, Chih-Yi Liao, Samuel Mehr, Jared Weiss, Robert A. Ramirez, Amir Iravani Iravani, Lucia Baratto, Wenjing Yang, Alaa Hanna, Stephen Michael Keefe, Markus Puhlmann, Vikas Prasad
Institutions: Mayo Clinic, Washington University in St. Louis, The Ohio State University, Johns Hopkins University, Michigan Healthcare Professionals, Virginia Cancer Specialists, Mayo Clinic in Florida, University of Kentucky, Markey Cancer Center, University of Chicago Medical Center, Nebraska Cancer Specialists, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162520157
Cites:
Cited by:
Related to: